Objective: Acute respiratory distress syndrome (ARDS) is a common complication in patients with non-pulmonary sepsis. Early identification and prediction of the occurrence of ARDS in non-pulmonary ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals currently has the industry's largest AI supercomputer. It also has partnerships with major drugmakers, but these have yet to yield major wins. Recursion'a lack of clinical ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

June 10 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding ...

We often think about the impact AI is making on profitable businesses and even governmental organizations, but AI is also making significant contributions to the operations and success of non-profit ...

MicroAlgo Inc. announced its research on the Quantum Information Recursive Optimization (QIRO) algorithm, which aims to address complex combinatorial optimization problems using quantum computing.

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...